Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin

Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin: Results From a Randomized Double Blinded Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04829903

Enrollment

116

Registered

2021-04-02

Start date

2020-01-02

Completion date

2021-11-20

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent Obesity, Obesity, Type 2 Diabetes Treated With Insulin

Brief summary

To compare the efficacy and effect on glycemic control of Dulaglutide versus Liraglutide in obese Type 2 diabetic adolescents using metformin

Detailed description

To observe the efficacy, effect on glycemic control, impact on BMI and incidence of adverse effects of Dulaglutide and to compare it to Liraglutide in individuals aged thirteen to eighteen who have Type 2 diabetes mellitus and are obese.

Interventions

DRUGDulaglutide

Dulaglutide injections

DRUGLiraglutide

Liraglutide injections

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to 19 Years

Healthy volunteers

Inclusion criteria

* Type 2 Diabetes Mellitus * Obese * Taking metformin * Male or female

Exclusion criteria

* Non obese * Not taking metformin * Taking other injectable diabetic medications

Design outcomes

Primary

Measure	Time frame	Description
Glycemic level	24 weeks for the duration of the study	HbA1c
BMI	24 weeks for the duration of the study	BMI measurements using weight and height measurements (anthropometric)
Adverse effects	24 weeks for the duration of the study	Recording of adverse effects

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026